The Board of Directors of Joincare, as the highest organ represent for Access to Healthcare issues, is responsible for understanding and monitoring the management of the Group's Access to Healthcare issues through the Sustainable Development Committee. The Sustainable Development Committee is responsible for regularly reviewing the Group's strategies, policies and performance on Access to Healthcare issues overseeing and reporting the progress to the Board of Directors, and urging the Group to improve access to healthcare.

To improve our product availability and make more safe and effective products available to global patients, Joincare expands the productionand marketing of vaccines, patent medicines, generics, APls, and IVD (In-Vitro Diagnostics) reagents and devices overseas mainly via direcoperation and authorising local distributors. So far, our products have been approved for registration in major pharmaceutical markets andemerging markets in multiple countries and areas across Asia, Europe. North America and Africa.

The Group continues to advance its internationalization strategy, deepening its global footprint through multi-dimensional initiatives and actively fulfilling its social responsibility with respect to global health accessibility. We actively introduce overseas innovative products and have successfully introduced drugs including Pixavir Marboxil Capsules, PREP inhibitors, and potassium-competitive acid blockers (P-CABs) as innovative drugs in the gastrointestinal field, enriching the product pipeline in our advantageous fields of respiratory and gastrointestinal health. We also pay special attention to medicine accessibility in low- and middle-income countries, and are committed to advancing the technology licensing and overseas expansion of high-end complex formulations so that high-quality medicines can benefit a broader patient population, fulfilling our responsibility for global health equity.

Joincare pays close attention to overseas markets and accelerates overseas business development. We continuously advance access, product registration, and promotion of inhalation formulations, assisted reproduction, gastrointestinal, and anti-infective products overseas. Multiple inhalation formulation products of the Group are preparing for registration filing in developing countries such as Malaysia and the Philippines, as well as EU member states including the Netherlands, Germany, and Italy; the two flagship products of Budesonide Suspension for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution together completed 6 batches of export to the Macao region.

In November 2025, Joincare Haibin's inhalation suspension (hormonal) and inhalation solution production lines passed the PIC/S GMP compliance inspection by Malaysia's NPRA and successfully obtained a GMP certificate, marking that the Group's production and quality management system meets international standards. This helps advance the registration and commercial launch of the Group's inhalation formulation products in Malaysia and other PIC/S member countries, laying a solid foundation for expanding into the Southeast Asian market.
At the same time, the company reached a deep cooperation agreement with PT KALBE FARMA, a major Southeast Asian pharmaceutical enterprise, with PT KALBE FARMA responsible for the registration and promotion of budesonide inhalation suspension in the Indonesian market, accelerating the benefits of high-quality medicines for Southeast Asian patients

Joincare is deeply aware that pharmaceutical costs are an important component of the economic burden of disease. Both domestically and across different countries, we adopt fair pricing policies based on product affordability to provide reasonably priced, high-quality medicines to more people in need, committed to reducing patients' economic burden.

The Group deeply recognizes that the national centralized drug procurement policy presents both an opportunity to fulfil social responsibility and a new opportunity for the Group's own development. Leveraging our strong R&D capabilities and production capacity, we have included many of our products in centralized drug procurement applications, transforming policy opportunities into practical benefits for the public and development momentum. While helping the country control healthcare costs and improve the efficiency of medical insurance fund utilization, we have significantly reduced patients' medication costs and improved medicine accessibility. Through the centralized drug procurement channels, the Group has further expanded market coverage and the population served, continuously injecting vitality into the advancement of healthcare.

When developing and expanding overseas markets, the Group has taken into account local economic development and healthcare levels as well as the pricing of comparable products, in order to set reasonable prices in line with regional development conditions and avoid adding to patients' economic burden. We fully assess per capita income levels in each region, analyze the affordability of local patients, and on this basis implement differentiated tiered pricing strategies across different markets. At the same time, during the promotion of products in developing countries overseas, we actively participate in local government tenders, committed to providing affordable medicines and services locally.

In response to the national strategy of rural revitalization and common prosperity, Joincare, joined hands with the Group’s holding subsidiary Livzon Group to carry on the long-term drug donation program – “Access to Public Welfare for Chronic Diseases Prevention and Treatment Programme”. We provided long-term assistance to patients with financial difficulties in remote areas who suffer from chronic diseases, such as hypertension, hyperlipidemia, cardiocerebral diseases and gastric diseases. We donated five drugs for treating chronic diseases, including Pravastatin Capsules (普伐他汀钠胶囊), Amlodipine Besylate Capsules (苯磺酸氨氯地平胶囊), Valsartan Capsules (缬沙坦胶囊), Isosorbide Mononitrate Tablets (单硝酸异山梨酯片) and Bismuth Potassium Citrate Tablets (枸橼酸铋钾片), to reduce the medical burden of chronic diseases on poor families and prevent patients from sinking back into poverty due to illness.

Since late 2018 onwards, we have carried out the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Programme” successively in areas including Chaotian District, Guangyuan City; Songpan County, Aba Zang Qiang Autonomous Prefecture; Jinkouhe District, Jiange and Pingwu Counties, Leshan City, Sichuan Province; Hunyuan, Guangling and Lingqiu Counties, Datong City, Shanxi Province; Dongxiang, Tianzhu, Linze, Shandan, Huining and Su’nan Counties, Gansu Province; Xianghai National Nature Reserve, Jilin Province; Macun District, Jiaozuo City, Henan Province; Huangshan District, Huangshan City, Anhui Province; Suining County, Hunan Province; Fenyi County, Jiangxi Province; Jiangshan City, Zhejiang Province; Chayu, Bomi, and Gerze Counties, Tibet Autonomous Region; Kashgar, Xinjiang Uygur Autonomous Region Baarin Left Banner and Togtoh County, Inner Mongolia Autonomous Region; and Ziyuan County, Guangxi Zhuang Autonomous Region. These are part of our efforts to benefit the public, protect the health of rural residents, revitalize rural areas, and build a beautiful and healthy China.

Respiratory diseases rank as the third most prevalent chronic condition in China, following cardiovascular diseases and diabetes. In recent years, the incidence of respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD) has been steadily rising. Epidemiological studies show that China has approximately 45.7 million adult asthma patients, 15 million children with asthma, and over 100 million COPD patients. We actively respond to the requirements of the "Healthy China 2030" strategy, systematically building an online and offline respiratory disease health education network. Through diverse approaches such as new media health live streams, publishing authoritative academic content, supporting cutting-edge clinical research, and organizing professional academic activities, we effectively improve public awareness of chronic diseases such as asthma and COPD, promote early lung function screening for high-risk populations, and take practical action to support the achievement of national respiratory disease prevention and control goals.

During "World Asthma Day" 2025, "Respiratory Experts' Views" focused on "Extending the Benefits of Inhalation Treatment to All Asthma Patients", conducting a series of health awareness lectures and health awareness live streams in over 200 cities across the country, spreading asthma health management and first aid knowledge through interactive activities such as health awareness Q&A, reaching millions of members of the public.

During "World Bronchiectasis Day" 2025, "Respiratory Experts' Views" partnered with 247 top-tier hospitals across the country to conduct health awareness activities, providing detailed introductions to the pathogenesis, diagnostic methods, and latest treatment advances for bronchiectasis.

During "World COPD Day" 2025, "Respiratory Experts' Views" participated in the "2025 World COPD Day health awareness Conference" jointly organized by the Guangzhou National Laboratory and the Guangdong Society for Respiratory Health, inviting multiple authoritative respiratory experts to discuss key topics including popularization of lung function testing, optimization of COPD diagnosis and treatment, innovation in non-pharmacological treatment, and winter protection.

The Group acknowledges that antibiotic resistance has become a global public health risk theme, threatening human health. We take measures to address antibiotic resistance mainly from the following three aspects:

Responsible production: During the production of antibiotics, we strictly control the discharge of wastewater, waste gas and waste residue to prevent antibiotics from entering the natural environment. We also refine the production process to improve the production efficiency of antibiotics and reduce waste generation.

Responsible use: In strict accordance with the Management Policy for Clinical Use of Antimicrobial Medicines, Joincare strictly regulates the clinical use of antibiotics and strengthens the management of its anti-infection product portfolio. Based on the classification of antibiotics for clinical use, we actively cooperate with medical institutions to handle antibiotic abuse, enforce the principles of “non-limited use”, “limited use”, and “special use”, and promote the management of physicians’ prescription rights and control of medicine-resistance bacteria. Training lessons and lectures on optimizing medicine-resistance bacteria treatment schemes are given to improve the clinical efficacy of antibiotics and effectively prevent misuse.

Responsible R&D: We continue to carry out R&D to limit or prevent antibiotic resistance, explore the mechanism of resistance through cooperation with third parties, and study new ways of drug administration by taking the advantage of fewer dosage of inhalation formulations to ensure reasonable drug administration.

Joincare is deeply committed to the development of healthcare in low- and middile-income countries. In line with our international strategies, we are actively involved in capacity advancement initiatives for healthcare in low- and middile-income countries and work closely with local partners to collectively improving the quality and capacity of health services in those regions.

While expanding our formulation business in developing countries, the Group actively provides training for local healthcare workers to improve local medical service standards. While we exported Meropenem for Injection to developing countries such as the Philippines, Ukraine, Vietnam, Pakistan, Peru, and Chile, we provided registration and promotion training for local contacts and assisted our partners in conducting product usage and related training for local healthcare workers. Also, Joincare’s holding subsidiary Livzon Group is actively engaged in overseas academic promotion and training activities. Livzon Group provides detailed product usage instructions and shares clinical experience with healthcare workers in developing countries, so as to ensure the safe and effective use of our products for local patients.

Assistance to local manufacturers to improve manufacturing quality

As an APIs supplier, Joincare, together with its holding subsidiary Livzon Pharmaceutical Group, shares its research results with less developed countries and regions overseas and proceeds technology transfer. We improve the capability of local manufacturers to ensure that they can achieve international drug manufacturing quality standards. By building API plants in Indonesia and introducing advanced production equipment and processes, we encourage local manufacturers to upgrade their production processes and technology applications. High-quality API production also helps local pharmaceutical companies produce more competitive drugs, improve drug accessibility, and meet the medical needs of local residents.

Supporting local pharmacovigilance

Pharmacovigilance work in developing countries started relatively late and progress has been slow, leaving a number of problems to be solved. We have distributors in Macao and the Philippines for drugs including the Compound Ipratropium Bromide Solution for Inhalation, Levosalbutamol Hydrochloride Nebuliser Solution, and Budesonide Suspension for Inhalation. To ensure the safe use of drugs in local areas, we have signed pharmacovigilance work agreements with overseas distributors and partners, and established the communication mechanism and work process for the pharmacovigilance teams of both sides. Our Pharmacovigilance Department is responsible for processing individual safety reports from local sites, conducting data evaluation, and reporting to domestic and foreign regulatory authorities. At the same time, through our agents, we investigate and monitor the use of our drugs overseas, conduct business training for local staff, receive regular adverse event reports, and help to improve the local pharmacovigilance system for these drugs.